Vinay Prasad, the FDA official responsible for overseeing vaccines, gene therapy, and blood product regulation, is returning to lead the Center for Biologics Evaluation and Research (CBER) following his unexpected resignation weeks ago. His abrupt departure was tied to tensions surrounding Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy and a politically charged campaign. The move comes at the FDA's request, signaling ongoing internal complexities within the agency’s leadership during a critical period for biologics and vaccine oversight.